Advancing our Immunoscience Pipeline

September 10, 2018

A

t the core of our research efforts, an understanding of the immune system has supported our fundamental study of how to treat diseases.  In our Immunoscience portfolio, we are currently advancing a pipeline of investigational assets with the goal of optimizing the body’s immune response.

This week, Bristol-Myers Squibb announced new data from our investigational tyrosine kinase (TYK2) inhibitor in moderate-to-severe plaque psoriasis.  Psoriasis is characterized by a rapid, unpredictable production of skin cells that leads to the formation of painful scaling and plaques, and can result in a significant impact on quality of life.  Despite the availability of therapies for psoriasis, the disease remains significantly undertreated, with patients struggling with insufficient disease control. The disease is often associated with multiple comorbidities.

Our goal in researching immune-mediated diseases, including psoriasis, is to discover, develop and deliver medicines for diseases with significant unmet medical needs.  Explore the articles below to read more about our research, including the TYK2 pathway and its role in immune-mediated diseases. 

Related Content